Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

23 April 2014: Lab/In Vitro Research  

The diagnostic importance of matrix metalloproteinase-7 and nestin in gastrointestinal stromal tumors

Kemal Peker ABCDEFG , Ilyas Sayar ABCDEF , İbrahim Gelincik BD , Gülay Bulut BC , Tuba Dilay Kökenek Ünal BC , Serkan Şenol BC , Aysun Gökçe BC , Arda Isik AEF

DOI: 10.12659/MSM.890303

Med Sci Monit 2014; 20:674-680

0 Comments

Abstract

BACKGROUND: The importance of the matrix metalloproteinase-7 (MMP-7) and nestin immunomarkers, C-kit proto-oncogene (CD117), and the efficiency of the Ki-67 proliferation index for gastrointestinal stromal tumors were evaluated.

MATERIAL AND METHODS: This study was conducted by examining the microscope slides of 72 patients with gastrointestinal stromal tumors that were sent to the pathology laboratory between 2007 and 2012. Immunohistochemical staining for CD117, MMP-7, nestin, and marker of proliferation Ki-67 was performed. The correlations between the positive results for Ki-67, CD117, MMP-7, and nestin were evaluated relative to the tumor characteristics of size, localization, grade, cellular type, cellularity, cytology type, growth pattern, ulceration, necrosis, hemorrhage, invasion depth, and lymph node metastasis.

RESULTS: The tumor was localized in the stomach in 42 of the patients, the intestines in 19, the colon in 7, and the rectum in 4. Comparisons among the groups showed that MMP-7 was correlated with the tumor grade (p<0.001), cellularity (p<0.009), cytologic atypia (p<0.001), ulceration (p=0.002), necrosis (p<0.001), and tumor size (p=0.001). Nestin was correlated with the tumor grade (p=0.013), and tumor size (p=0.024). Correlations among CD117, MMP-7, nestin, and Ki-67 were examined. Nestin and Ki-67 were both significantly correlated with CD117 and MMP-7 [(r=0.279, p=0.018), (r=0.322, p=0.006), (r=0.386, p=0.001), (r=0.386, p=0.002)], respectively.

CONCLUSIONS: MMP-7 and nestin may be beneficial as markers, given their sensitivity to gastrointestinal stromal tumors.

Keywords: Aged, 80 and over, Cell Nucleus - pathology, Gastrointestinal Stromal Tumors - pathology, Ki-67 Antigen - metabolism, Matrix Metalloproteinase 7 - metabolism, Nestin - metabolism, Proto-Oncogene Proteins c-kit - metabolism, Staining and Labeling

Background

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors with specific histological characteristics that are primarily localized in the gastrointestinal system and abdomen. Normally, interstitial Cajal cells, which regulate peristalsis in the gastrointestinal system, are found in and around the myenteric plexus of the intestinal wall. It is thought that GISTs are mesenchymal tumors originating from Cajal cell precursors [1] and that a mutation in the C-kit proto-oncogene (CD117) protein found in the Cajal cells plays a role in the pathogenesis of the GISTs. In some of these tumors, a mutation in the platelet-derived growth factor receptor alpha gene, another tyrosine kinase proto-oncogene, is seen instead of the C-kit mutation, but in others, no mutation is detected [2–4]. CD117 acts as a receptor for growth and stem cell factors, and the receptor-ligand relationship between these factors and C-kit activates internal tyrosine kinase, which is followed by the phosphorylation of intracellular proteins and the activation of cell signaling pathways. These series of events are important in regulating the proliferation, apoptosis, adhesion, and differentiation in many cell types, including the interstitial Cajal cells [5].

While C-kit activation is sufficient for interstitial Cajal cell hyperplasia, additional oncogenic events are required for actual neoplastic GIST formation [3]. Since omental and mesenteric primary stromal tumors display the typical immunohistochemical profile of GISTs, and since interstitial Cajal cells are not found in this location, it is believed that GIST may develop from multipotent mesenchymal stem cells (interstitial mesenchymal precursors) [6].

Matrix metalloproteinases (MMPs) are calcium-dependent endopeptides containing zinc, which are involved in the disruption of the extracellular matrix and remodeling of the tissue. The MMPs provide hemostasis by increasing in normal tissue at the physiological state [7]. Nestin is an intermediate filament protein that is responsible for the rapid division of progenitor cells during tissue renewal and development [8]. The labile marker of proliferation Ki-67 is a non-histone nuclear protein that is closely related to the cell cycle and growth, the mid-G1, S, and G2 phases of the cell cycle, and mitosis [9].

Currently, the most valid immunohistochemical method for diagnosing GISTs is the demonstration of the C-kit mutation in CD117 [10]. In our study, we examined the expression of the MMP-7 and nestin immunomarkers and CD117, and evaluated the efficiency of the Ki-67 proliferation index.

Material and Methods

STATISTICAL ANALYSIS:

Mann Whitney U tests and one-way ANOVAs were used to compare the ages of the patients between groups based on the assumed parametric distribution. Ages are presented as the mean ± standard deviation. Categorical variables were compared by Pearson, Yates, or Fisher chi-square tests and are presented as a count and percentage. Spearman correlation coefficients were used to determine the correlations between CD117, MMP-7, nestin, Ki-67 and the other parameters. The sensitivity and specificity of MMP-7 and nestin were calculated to compare their diagnostic performance to CD117 as the criterion standard. The IBM SPSS Statistics 20 (SPSS Inc., IBM Corporation, Armonk, NY, USA) and MedCalc 12.7.8 (MedCalc Software, Ostend, Belgium) programs were used to perform the analyses, and a p-value <0.05 was considered significant.

Results

The tumor was localized in the stomach in 42 of the patients (58.3%), the intestines in 19 patients (26.4%), the colon in 7 patients (9.7%), and the rectum in 4 patients (5.6%). Of the 3 risk groups, 28 (38.9%) patients were in the L risk group, 23 (31.9%) were in the IM risk group, and 21 (29.2%) were in the H risk group. The tumor was <5 cm in 33 of the patients (45.8%), 5–10 cm in 24 patients (33.3%), and >10 cm in 15 patients (20.8%). Four of the cases included epithelioid cells (5.6%), while 49 had fusiform cells (68.1%) and 19 contained mixed-type cells (26.4%). We also determined that cellularity was present in 53 cases (73.6%) and absent in the other 19 (26.4%). In addition, both ulceration and necrosis were present in 22 cases (30.5%), but absent in 50 (69.5%). Furthermore, we found that hemorrhage was present in 37 cases (51.4%) and absent in 35 (48.6%), whereas cytologic atypia was present in 19 cases (26.4%), mild in 39 cases (54.2%), and absent in 14 cases (19.4%). Seventeen (23.6%) of the GISTs were located in the submucosa, 19 (26.4%) were found in the muscle layer, and 36 (50%) appeared to have extended to the serosa. We also found that 63 (86.1%) of the cases were expansive, while only 10 (13.9%) were infiltrative.

For the immunohistochemical staining with CD117, 13 (18.1%) of the 72 cases were classified as +, 6 (8.3%) as ++, and 51 (70.8%) as +++, while 2 (2.8%) were negative for CD117 staining. In the L risk group, no staining was seen in 1 of the 28 samples (3.5%), 7 (25%) were classified as +, 2 (7%) as ++, and 18 (64.5%) as +++. In the 23 cases in the IM risk group, 1 (4.4%) tested negative, while 5 (21.7%) showed + staining, 4 (17.4%) had ++ staining, and 13 (56.5%) had +++ staining. Lastly, in the 21 samples in the H risk group, 1 (4.8%) had + staining and 20 (95.2%) showed +++ staining (Figure 1). Correlations of CD117 with the other groups (nestin, MMP7, and Ki 67) showed that the parameters of localization, and grade were statistically significant. However, no significant correlations were found between CD117 positivity and tumor size, cellularity, cytologic atypia, ulceration, necrosis, hemorrhage, or invasion depth.

With regard to the immunohistochemical staining for MMP-7, 5 (6.9%) of the 72 cases were categorized as +, 29 (40.3%) as ++, and 37 (51.4%) as +++. One (1.4%) of the samples in this group was negative. In the 28 cases in the L risk group, 1 (3.5%) showed no staining, 2 (7%) had + staining, 19 (68%) indicated ++ staining, and 6 (21.5%) showed +++ staining. For the 23 cases in the IM risk group, 1 (4.4%) had + staining, 9 (39.1%) had ++ staining, and 13 (56.5%) had +++ staining. In the H risk group, which consisted of 21 cases, 2 (9.5%) were classified as +, 1 (4.8%) as ++, and 18 (85.7%) as +++ (Figure 2).

When testing for nestin, we found that 3 (4.1%) of the 72 cases showed + staining, 4 (5.6%) showed ++ staining, and 63 (87.5%) had +++ staining. Two (2.8%) of the cases were negative for nestin. Of the 28 L risk group samples, 1 (3.5%) was negative, 2 (7%) showed + staining, 3 (10.5%) had ++ staining, and 22 (79%) had +++ staining. Of the 23 cases in the IM risk group, 1 (4.4%) was negative, 1 (4.4%) showed + staining, 1 (4.4%) had ++ staining, and 20 (86.8%) showed +++ staining. Finally, in the 21 cases in the H risk group, all of the samples (100%) were categorized as +++ (Figure 3). There were no statistically significant differences for patients’ characteristics. For Ki-67, there were statistically significant differences for the localization, grade, cellularity, cytologic atypia, necrosis, hemorrhage, invasion depth, and tumor size, but not with the other patient characteristics (Table 1; Figure 4).

When we stained the samples for Ki-67, 37 (51.4%) of the cases were below 1%, 19 (26.4%) were between 1% and 10%, and 16 (22.2%) were above 10%. In the L risk group, 26 (93%) of the 28 cases showed <1% staining, and 2 (7%) had 1–5% staining. In the IM risk group, 10 (44%) of the 23 cases showed <1% staining and 13 had 1–10% staining. In the H risk group, only 1 (4.8%) of the 21 cases had <1% staining, whereas 4 had 1–10% staining and 16 showed >10% staining.

Correlation coefficients were calculated between the positive results for CD117, MMP-7, nestin, and Ki-67 with the tumor size, localization, grade, cellularity, cytologic atypia, ulceration, necrosis, hemorrhage, and invasion depth. For CD117, the correlations between the groups showed that tumor localization and tumor grade were statistically significant. For the MMP-7 correlations, the tumor grade, cellularity, cytologic atypia, ulceration, necrosis, and tumor size were statistically significant. For the nestin correlations, the tumor grade and tumor size were statistically significant, and for Ki67 all of the variables were significantly correlated (Table 2). When correlations among CD117, MMP-7, nestin, and Ki-67 were examined, nestin and Ki-67 were both significantly correlated with CD117 and MMP-7 (Table 3).

When the diagnostic performances of the MMP-7 and nestin results relative to CD117 were examined, the sensitivities were 92.98% and 98.25%, respectively, and the specificities were 13.33% and 26.67%. Both methods were strong at determining real positivity and weak at determining real negativity.

Discussion

Gastrointestinal stromal tumors usually remain silent until they reach a large diameter, and the symptoms they present with at that point vary according to the tumor localization and dimension. These tumors usually manifest in conjunction with nonspecific symptoms such as abdominal pain, loss of appetite, nausea, anorexia, weight loss, fever, and obstruction. The patients may also present with life-threatening intraperitoneal hemorrhage as a result of massive bleeding due to a chronic or mucosal ulceration or rupture. In some patients, the mass may be palpable [14,15], and aggressive GISTs may produce metastases in the liver or anywhere in the abdomen [16]. To make an appropriate diagnosis, the GISTs need to be classified, and the prognosis is then determined according to the immunohistochemical and morphological characteristics of the tumor [17,18].

One of the most important properties used to describe GISTs is the expression of the C-kit protein because it is present in most of these tumors, and the immunomarker for C-kit expression is CD117 [19,20]. As expected, we found that 70 of 72 of our cases tested positive for CD117.

It has been suggested that MMP-7 is excessively expressed in tissues with tumors and is related to other processes such as apoptosis, invasion, metastasis, and angiogenesis [21]. We found MMP-7 was positively expressed in 71 patients, with only 1 sample testing negative. Furthermore, correlations of MMP-7 with the other groups (nestin, CD117, and Ki 67) showed that the parameters of grade, cellularity, cytological atypia, ulceration, necrosis, and tumor size were statistically significant. However, no significant correlations were found between MMP-7 positivity localization, hemorrhage, or invasion depth. Similarly, in a study by Ding Li et al. [22] that included 68 GIST cases, they determined that the expression of the immunomarkers increased in line with higher Fletcher risk rates, and as a result, MMP-3 and MMP-7 staining increased.

Nestin is an intermediate filament involved in the proliferation and development of fetal and embryonic cells. It is also involved in the expression of adult stem and progenitor cell populations, including vascular endothelial, striated muscle, hair follicle precursor, islet precursor, and liver cells. In addition, nestin is reactivated in cases of trauma and other pathological conditions [23–27]. Enache et al. [28] found that 63 of the 81 patients in their study with GISTs tested positive for nestin. We found 70 of our 72 samples stained positive for nestin, with only 3 staining mildly, and 2 moderately. We identified significant correlations between the samples that tested positive for nestin and tumor grade and tumor size, whereas no significant correlations were found between nestin and localization, cellularity, cytologic atypia, growth pattern, ulceration, necrosis, hemorrhage, or invasion depth.

With GISTs, the mitotic rate is related to the prognosis. The immunomarker Ki-67 can be used to calculate a proliferation index [29]. In a study involving 113 patients with GISTs, Liu et al. [30] found that 74 (65.5%) tested positive for Ki-67. In our study, we found that 100% of our cases were positive for Ki-67. While significant correlations were found between the samples that tested positive for Ki-67, CD117, and nestin, no significant correlation was identified with MMP-7 positivity. In a study by Fletcher et al. [11], increased Ki-67 proliferation index rates were seen with high-risk GISTs, and we similarly found that these rates became higher as the tumor grade increased.

The CD117 positive and negative groups were significantly correlated with those of Ki-67 and nestin, but there were no statistically significant correlations with other patient characteristics. There were also no patient characteristics correlated with the positive and negative MMP-7 groups.

Conclusions

Consistent staining with nestin and MMP-7 showed that these immunomarkers were sensitive to GISTs, regardless of the cell type and tumor grade. Additionally, positive correlations were seen with regard to nestin and MMP-7 and the tumor grade, which suggests that these markers might play an important role in the development of GISTs. Furthermore, Ki-67 should be evaluated as a prognostic factor in association with CD117, since it is used in the diagnosis of these tumors. Our findings also indicate that MMP-7 and nestin may be beneficial markers given their sensitivity to GISTs.

References

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM, Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal: Am J Pathol, 1998; 152; 1259-69, pmid: 9588894

2. Blay JY, Bonvalot S, Casali P, GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors: Ann Oncol, 2005; 16; 566-78, pmid: 15781488

3. Heinrich M, Rubin B, Longley B, Fletcher J, Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations: Hum Pathol, 2002; 33; 484-95, pmid: 12094373

4. Heinrich M, Corless C, Demetri G, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour: J Clin Oncol, 2003; 21; 4342-49, pmid: 14645423

5. Sturgeon C, Chejfec G, Espat NJ, Gastrointestinal stromal tumors: a spectrum of disease: Surg Oncol, 2003; 12; 21-26, pmid: 12689667

6. Duffaud F, Blay JY, Gastrointestinal stromal tumors: biology and treatment: Oncology, 2003; 65; 187-97, pmid: 14657591

7. Verma RP, Hansch C, Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs: Bioorg Med Chem, 2007; 15; 2223-68, pmid: 17275314

8. Michalczyk K, Ziman M, Nestin structure and predicted function in cellular cytoskeletal organisation: Histol Histopathol, 2005; 20; 665-71, pmid: 15736068

9. Park D, Kåresen R, Noren T, Sauer T, Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications: Virchows Arch, 2007; 451; 11-18, pmid: 17554555

10. Demetri GD, Benjamin RS, Blanke CD, NCCN Task Force Report: Management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN Clinical Practice Guidelines: J Natl Compr Canc Netw, 2007; 5; 1-29

11. Fletcher C, Berman J, Corless C, Diagnosis of gastrointestinal stromal tumors: a consensus approach: Hum Pathol, 2002; 33; 478-83, pmid: 12094372

12. Yang XH, Wu QL, Yu XB, Nestin expression in different tumours and its relevance to malignant grade: J Clin Pathol, 2008; 61; 467-73, pmid: 17873113

13. Okayama H, Kumamoto K, Saitou K, CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer: Oncol Rep, 2009; 22; 745-55, pmid: 19724852

14. Ueyama T, Guo KJ, Hashimoto H, A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors: Cancer, 1992; 69; 947-55, pmid: 1735086

15. Miettinen M, Sarlomo-Rikala M, Sobin LH, Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases: Am J Surg Pathol, 2000; 24; 1339-52, pmid: 11023095

16. DeMatteo RP, Lewis JJ, Leung D, Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival: Ann Surg, 2000; 231; 51-58, pmid: 10636102

17. Miettinen M, El-Rifai W, Sobin LH, Lasota J, Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a rewiew: Human Pathology, 2002; 33; 478-83, pmid: 12094372

18. Wong NACS, Young R, Malcomson RDG, Prognostic indicators for gastrointestinal stromal tumors: a clinipathological and immunohistochemical study of 108 resected cases of the stomach: Histopathology, 2003; 43; 118-26, pmid: 12877726

19. Blackstein ME, Blay JY, Corless C, Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment: Can J Gastroenterol, 2006; 20; 157-63, pmid: 16550259

20. Corless CL, Fletcher JA, Heinrich MC, Biology of gastrointestinal stromal tumors: J Clin Oncol, 2004; 22; 3813-25, pmid: 15365079

21. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM, Matrix metalloproteinases: biologic activity and clinical implications: J Clin Oncol, 2000; 18; 1135-49, pmid: 10694567

22. Li Ding, Xiang-Rui Ji, Jie Zhao, Expression of MMP3 MMP7, AND timp1 in gastrointestinal stromal tumor: Medical Journal of Qilu, 2009; 3

23. Amoh Y, Yang M, Li L, Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis: Cancer Res, 2005; 65; 5352-57, pmid: 15958583

24. Sejersen T, Lendahl U, Transient expression of the intermediate of the intermediate filament nestin during skeletal muscle development: J Cell Sci, 1993; 106; 1291-300, pmid: 8126108

25. Li L, Mignone J, Yang M, Nestin expression in hair follicle sheath progenitor cells: Proc Natl Acad Sci USA, 2003; 100; 9958-61, pmid: 12904579

26. Maria-Engler SS, Correa-Giannella ML, Labriola L, Co-localization of nestin and insulin and expression of islet cell markers in long-term human pancreatic nestin-positive cell cultures: J Endocrinol, 2004; 183; 455-67, pmid: 15590972

27. Gleiberman AS, Encinas JM, Mignone JL, Expression of nestin – green fluorescent protein transgene marks oval cells in the adult liver: Dev Dyn, 2005; 234; 413-21, pmid: 16127706

28. Enache S, Arsene D, Iosif C, Nestin and caveolin-1 in the diagnosis of GISTs: Rom J Morphol Embryol, 2012; 53; 41-46, pmid: 22395498

29. Hamilton SR, Aaltonen LA, Pathology and Genetics of tumours of the digestive system: World Health Organization classification of tumours, 2000, Lyon, IARC Press

30. Liu LC, Xu WT, Wu X, Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors: World J Gastroenterol, 2013; 19; 2473-80, pmid: 23674848

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750